Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $30.6 million.

  • Northwest Biotherapeutics' Liabilities and Shareholders Equity rose 439.28% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.4 million, marking a year-over-year increase of 36.06%. This contributed to the annual value of $26.7 million for FY2024, which is 408.04% down from last year.
  • Northwest Biotherapeutics' Liabilities and Shareholders Equity amounted to $30.6 million in Q3 2025, which was up 439.28% from $29.5 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Liabilities and Shareholders Equity ranged from a high of $40.2 million in Q4 2021 and a low of $26.7 million during Q4 2024
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $29.3 million (2024), whereas its average is $30.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 25347.93% in 2021, then crashed by 2200.45% in 2022.
  • Northwest Biotherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $40.2 million in 2021, then decreased by 22.0% to $31.3 million in 2022, then dropped by 11.04% to $27.9 million in 2023, then decreased by 4.08% to $26.7 million in 2024, then increased by 14.52% to $30.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $30.6 million in Q3 2025, compared to $29.5 million in Q2 2025 and $27.5 million in Q1 2025.